Pharmabiz6d
Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies
Genethon & Eukarÿs enter strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies: Evry, France Friday, January 24, 2025, ...
Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of gene therapies
Press release Genethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the ...
Chromatin Bioscience's Synthetic Promoter Supports Esobiotec's ESO-T01 CAR-T Therapy As It Enters The Clinic
EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antigen (BCMA) CAR-T candidate to reach the clinical ...
eLife10d
Wnt specifically induces FZD5/8 endocytosis and degradation and the involvement of RSPO-ZNRF3/RNF43 and DVL
Frizzled (FZD) proteins are the principal receptors of the Wnt signaling pathway. However, whether Wnt ligands induce FZD endocytosis and degradation remains elusive. The transmembrane E3 ubiquitin ...
Benitec Biopharma: Early Positive Data, Small Target Market, Little Competition
Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small ...
eLife8d
TET2-mediated epigenetic modification promotes stress senescence of pancreatic β cells in type 2 diabetes mellitus
This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...
BioSpace3d
Duchenne Muscular Dystrophy Space on Cusp of Pivotal Era
While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population
Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...
Le Lézard17d
Spatial Genomics & Transcriptomics Market to Hit USD 995.7 Million by 2029 with 12.4% CAGR | MarketsandMarketstm
The growing need for exact gene expression profiling in diseases research and medication ... Insights at Advanced Therapies Week on January 21-22, 2025 Caring Cross and Vector BioMed, Inc. are pleased ...